What is stock analysis? Well, there are some that think it has everything to do with the dividend. There are others that only look at charts. There are others that think analyst estimate misses (notice how this is equivalent to companies' earnings beats) are a way to gauge the trajectory of a stock. And yet there are others who are lost in medieval times. We, as investors, need to move beyond these individual frameworks and start taking a holistic view. Let's take a look at what we mean as it relates to our analysis of Walgreen Company (WAG).
But first, a little background to help everyone understand our article and process better. At Valuentum, we think a comprehensive analysis of a firm's discounted cash-flow valuation (based on long-term expectations) and relative valuation versus industry peers (competitors if available) is the best way to identify the most attractive stocks. This process culminates in what we call our Valuentum Buying Index (VBI), which ranks stocks on a scale from 1 to 10, with 10 being the best.
Walgreen posts a VBI score of 3 on our scale, reflecting our 'fairly valued' DCF assessment of the firm, its neutral relative valuation versus peers, and bearish technicals. Though we note that the following firms aren't direct competitors, we compare Walgreen to industry peers Costco (COST), Target (TGT), and Wal-Mart (WMT) to help financial advisors gain perspective on the potential valuation opportunities across the industry. In the spirit of transparency, we show how the performance of the Valuentum Buying Index has performed per underlying score (based on the last update):
- Walgreen's business quality (an evaluation of our ValueCreation™ and ValueRisk™ ratings) ranks among the best of the firms in our coverage universe. The firm has been generating economic value for shareholders with relatively stable operating results for the past few years, a combination we view very positively.
- Walgreen operates the largest drugstore chain in the US, with prescription drug sales representing about two thirds of its business. The company's integrated network of pharmacies allows easy access for customers to fill their prescriptions at any of its drugstores.
- Walgreen's cash flow generation and financial leverage aren't much to speak of. The firm's free cash flow margin has averaged about 3.8% during the past three years, lower than the mid-single-digit range we'd expect for cash cows. However, the firm's cash flow should be sufficient to handle its low financial leverage.
- Though we like Walgreen quite a bit, if its participation in any of the programs run by one or more of the large PBMs is terminated, results would suffer.
Economic Profit Analysis
The best measure of a firm's ability to create value for shareholders is expressed by comparing its return on invested capital - ROIC - with its weighted average cost of capital - WACC. The gap or difference between ROIC and WACC is called the firm's economic profit spread. Walgreen's 3-year historical return on invested capital (without goodwill) is 15.4%, which is above the estimate of its cost of capital of 9.3%. As such, we assign the firm a ValueCreation™ rating of EXCELLENT. In the chart below, we show the probable path of ROIC in the years ahead based on the estimated volatility of key drivers behind the measure. The solid grey line reflects the most likely outcome, in our opinion, and represents the scenario that results in our fair value estimate.
Cash Flow Analysis
Firms that generate a free cash flow margin (free cash flow divided by total revenue) above 5% are usually considered cash cows. Walgreen's free cash flow margin has averaged about 3.8% during the past 3 years. As such, we think the firm's cash flow generation is relatively MEDIUM. The free cash flow measure shown above is derived by taking cash flow from operations less capital expenditures and differs from enterprise free cash flow (FCFF), which we use in deriving our fair value estimate for the company. For more information on the differences between these two measures, please visit our website at Valuentum.com. At Walgreen, cash flow from operations increased about 18% from levels registered two years ago, while capital expenditures expanded about 53% over the same time period.
The estimated fair value of $48 per share represents a price-to-earnings (P/E) ratio of about 19.9 times last year's earnings and an implied EV/EBITDA multiple of about 10 times last year's EBITDA. Our model reflects a compound annual revenue growth rate of 3.8% during the next five years, a pace that is lower than the firm's 3-year historical compound annual growth rate of 4.2%. Our model reflects a 5-year projected average operating margin of 6.3%, which is above Walgreen's trailing 3-year average. Beyond year 5, we assume free cash flow will grow at an annual rate of 2.9% for the next 15 years and 3% in perpetuity. For Walgreen, we use a 9.3% weighted average cost of capital to discount future free cash flows.
Margin of Safety Analysis
Our discounted cash flow process values each firm on the basis of the present value of all future free cash flows. Although we estimate the firm's fair value at about $48 per share, every company has a range of probable fair values that's created by the uncertainty of key valuation drivers (like future revenue or earnings, for example). After all, if the future was known with certainty, we wouldn't see much volatility in the markets as stocks would trade precisely at their known fair values. Our ValueRisk™ rating sets the margin of safety or the fair value range we assign to each stock. In the graph below, we show this probable range of fair values for Walgreen. We think the firm is attractive below $38 per share (the green line), but quite expensive above $58 per share (the red line). The prices that fall along the yellow line, which includes our fair value estimate, represent a reasonable valuation for the firm, in our opinion.
Future Path of Fair Value
We estimate Walgreen's fair value at this point in time to be about $48 per share. As time passes, however, companies generate cash flow and pay out cash to shareholders in the form of dividends. The chart below compares the firm's current share price with the path of Walgreen's expected equity value per share over the next three years, assuming our long-term projections prove accurate. The range between the resulting downside fair value and upside fair value in Year 3 represents our best estimate of the value of the firm's shares three years hence. This range of potential outcomes is also subject to change over time, should our views on the firm's future cash flow potential change. The expected fair value of $60 per share in Year 3 represents our existing fair value per share of $48 increased at an annual rate of the firm's cost of equity less its dividend yield. The upside and downside ranges are derived in the same way, but from the upper and lower bounds of our fair value estimate range.
Pro Forma Financial Statements
(click to enlarge)
(click to enlarge)